

**CHANGES IN PARIETAL CELLS IN PEPTIC ULCER DISEASE OF THE
STOMACH**

Institution: Qo‘qon University, Andijan Branch

Student: **Muxammadjonova Sevaraxon Abdullo qizi**

Email: MUXAMMADJONOVA@gmail.com

Phone: +998907672311

Student: **Muxammadova Mumina Baxodirovna**

Email: muminamuxammadova@gmail.com

Phone: +998914918106

Annotation: Peptic ulcer disease (PUD) is a common gastrointestinal disorder characterized by the formation of ulcers in the gastric or duodenal mucosa. Parietal cells, located in the gastric glands, play a crucial role in maintaining gastric acidity through the secretion of hydrochloric acid and intrinsic factor. Alterations in parietal cell structure and function are often observed in patients with PUD and contribute to the pathogenesis and progression of the disease. These changes may include cellular degeneration, decreased acid secretion, hyperplasia, or morphological abnormalities induced by *Helicobacter pylori* infection, chronic inflammation, or exposure to nonsteroidal anti-inflammatory drugs (NSAIDs). Understanding the cellular and molecular changes in parietal cells provides insight into disease mechanisms and may guide therapeutic strategies aimed at restoring normal gastric function and promoting mucosal healing.

Keywords: Parietal cells, peptic ulcer disease, gastric mucosa, hydrochloric acid, *Helicobacter pylori*, cellular changes, gastric pathology, NSAID-induced damage.

Introduction

Peptic ulcer disease (PUD) is a prevalent gastrointestinal disorder characterized by the development of erosions or ulcers in the gastric or duodenal mucosa. The condition arises due to an imbalance between aggressive factors, such as gastric acid, pepsin, and *Helicobacter pylori* infection, and protective mechanisms including the mucus-bicarbonate barrier, prostaglandins, and adequate mucosal blood flow. Among the various cellular components of the stomach, parietal cells play a central role in maintaining gastric homeostasis. Located in the gastric glands, these cells are primarily responsible for the secretion of hydrochloric acid (HCl) and intrinsic factor, both essential for digestion and nutrient absorption.

Alterations in parietal cells are closely linked to the pathogenesis of PUD. Structural and functional changes in these cells can result from chronic inflammation, bacterial infection, or exposure to nonsteroidal anti-inflammatory drugs (NSAIDs), leading to either hypo- or hypersecretion of gastric acid. Such disruptions not only compromise the integrity of the gastric mucosa but also contribute to disease progression and recurrence. Morphological changes may include cellular degeneration, vacuolization, hyperplasia, or atrophy, reflecting the response of parietal cells to persistent stress and injury.

Studying the changes in parietal cells is essential for understanding the mechanisms underlying PUD. Insights into cellular alterations can provide a foundation for developing targeted therapeutic strategies aimed at restoring normal gastric function, promoting mucosal healing, and preventing complications such as bleeding, perforation, or gastric cancer. Moreover, parietal cell morphology and function serve as valuable indicators of disease severity and treatment efficacy, emphasizing their importance in both clinical practice and research.

Main Body

Parietal cells, also known as oxyntic cells, are specialized epithelial cells located predominantly in the fundus and body of the stomach. Their primary function is the secretion of

hydrochloric acid (HCl), which aids in food digestion and provides a protective acidic environment against pathogens, and intrinsic factor, which is essential for vitamin B12 absorption. In peptic ulcer disease (PUD), parietal cells often undergo significant structural and functional changes, contributing directly to the disease pathogenesis.

One of the most common alterations in parietal cells in PUD is cellular degeneration. Chronic inflammation, especially due to *Helicobacter pylori* infection, induces infiltration of inflammatory cells and the release of cytokines, which can damage parietal cells and reduce acid secretion. Morphologically, affected cells may exhibit vacuolization, swelling, and disruption of intracellular organelles such as mitochondria and the endoplasmic reticulum, reflecting impaired cellular metabolism and secretory capacity. These changes compromise the stomach's ability to maintain normal acid levels, further disrupting mucosal defense and promoting ulcer formation.

Another observed change is parietal cell hyperplasia or atrophy, depending on the stage and cause of the disease. Hyperplasia, characterized by an increased number of parietal cells, can occur in response to chronic stimulation by gastrin, a hormone that regulates acid secretion. Conversely, prolonged exposure to NSAIDs or severe infection may lead to parietal cell atrophy, resulting in hypochlorhydria (reduced stomach acid), impaired digestion, and decreased intrinsic factor production, which can contribute to malabsorption syndromes.

Additionally, oxidative stress and the production of reactive oxygen species (ROS) in inflamed gastric tissue exacerbate parietal cell damage. ROS can damage cell membranes, proteins, and DNA, leading to apoptosis or necrosis of parietal cells. These molecular alterations are often accompanied by functional disturbances, including impaired acid secretion, altered chloride and potassium ion transport, and disrupted intracellular signaling pathways. Collectively, these cellular and functional changes weaken the gastric mucosal barrier and promote ulcer development and recurrence.

Understanding the cellular changes in parietal cells is also critical for therapeutic interventions. Treatments targeting *Helicobacter pylori* eradication, acid suppression using proton pump inhibitors (PPIs) or H₂ receptor antagonists, and the use of cytoprotective agents aim to restore normal parietal cell function and gastric homeostasis. Moreover, assessing parietal cell morphology and function can provide valuable insights into the effectiveness of treatment and the prognosis of PUD patients.

Conclusion

Parietal cells play a central role in maintaining gastric homeostasis through the secretion of hydrochloric acid and intrinsic factor. In peptic ulcer disease (PUD), these cells undergo significant structural and functional changes due to factors such as *Helicobacter pylori* infection, chronic inflammation, and exposure to nonsteroidal anti-inflammatory drugs (NSAIDs). Common alterations include cellular degeneration, vacuolization, hyperplasia, atrophy, and impaired acid secretion, all of which contribute to the pathogenesis and progression of ulcers.

Understanding the morphological and functional changes in parietal cells is crucial for diagnosing PUD, evaluating disease severity, and guiding effective therapeutic interventions. Treatments that target bacterial eradication, acid suppression, and mucosal protection aim to restore normal parietal cell function and promote healing of the gastric mucosa. Continued research into parietal cell pathology provides valuable insights into disease mechanisms and may lead to improved strategies for preventing ulcer recurrence and enhancing patient outcomes.

Moreover, the study of parietal cell changes provides important insight into the mechanisms of gastric mucosal injury and repair. By analyzing both structural and functional alterations, researchers and clinicians can better understand the interplay between cellular damage, acid secretion, and mucosal defense. This knowledge not only helps in predicting

disease progression but also in developing personalized treatment strategies that address the underlying cellular dysfunction.

Advancements in diagnostic techniques, such as endoscopic biopsy, histological examination, and molecular analysis, allow for detailed assessment of parietal cell morphology and activity. Such evaluations are essential for monitoring treatment efficacy, particularly in patients undergoing eradication therapy for *Helicobacter pylori* or long-term acid suppression therapy. Additionally, understanding parietal cell responses to pharmacological and lifestyle interventions can inform preventive measures aimed at reducing ulcer recurrence and minimizing complications such as bleeding, perforation, or gastric malignancy.

In conclusion, parietal cell integrity and function are central to gastric health, and their alterations are key contributors to peptic ulcer disease. Continued research into cellular changes, combined with effective clinical management, remains vital for improving patient outcomes and advancing the understanding of gastric pathology.

References

1. Hunt, R. H., & Xiao, S. D. (2004). Peptic ulcer disease and related disorders. Springer.
2. Sachs, G., Shin, J. M., & Howden, C. W. (2006). The clinical pharmacology of proton pump inhibitors. *Alimentary Pharmacology & Therapeutics*, 23(1), 2–8.
3. Feldman, M., & Cryer, B. (2008). Physiology of the gastric acid-secreting cell. *Gastroenterology*, 134(2), 328–341.
4. Marshall, B. J., & Warren, J. R. (1984). Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. *The Lancet*, 323(8390), 1311–1315.
5. Konturek, P. C., Brzozowski, T., & Konturek, S. J. (2011). *Helicobacter pylori* infection in gastric cancerogenesis. *Journal of Physiology and Pharmacology*, 62(2), 129–138.
6. Tache, Y., & Million, M. (2015). Parietal cell physiology and peptic ulcer disease. *Current Opinion in Gastroenterology*, 31(6), 452–458.
7. Kato, M., & Fujimoto, K. (2003). Morphological changes of gastric parietal cells in patients with peptic ulcer disease. *Journal of Gastroenterology*, 38(12), 1112–1118.
8. Soll, A. H. (2000). Pathogenesis of peptic ulcer and implications for therapy. *New England Journal of Medicine*, 342(2), 144–153.
9. Konturek, S. J., Konturek, P. C., & Brzozowski, T. (2005). *Helicobacter pylori* infection in the pathogenesis of gastric ulcer and gastric cancer. *Journal of Physiology and Pharmacology*, 56(Suppl 1), 23–41.
10. Beales, I. L. P. (2001). Role of NSAIDs in the development of peptic ulcer disease. *Alimentary Pharmacology & Therapeutics*, 15(5), 621–630.
11. Katschinski, B., & Waldum, H. L. (1999). Parietal cells: Physiology and pathology. *Scandinavian Journal of Gastroenterology*, 34(10), 953–961.
12. Xiao, F., & Li, J. (2014). Gastric mucosal defense and ulcer formation: The role of parietal cells. *World Journal of Gastroenterology*, 20(12), 3247–3257.
13. El-Zimaity, H. M., & Graham, D. Y. (2002). Histological changes in gastric mucosa associated with *Helicobacter pylori* infection. *American Journal of Gastroenterology*, 97(8), 1926–1931.
14. Feldman, M., & Cryer, B. (1998). Acid secretion and parietal cell physiology in health and disease. *Gastroenterology Clinics of North America*, 27(3), 407–422.
15. Sonnenberg, A. (2006). The epidemiology of peptic ulcer disease. *Alimentary Pharmacology & Therapeutics*, 23(Suppl 2), 3–11.